Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Gross Margin for 4 consecutive years, with 79.42% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin fell 752.0% year-over-year to 79.42%; the TTM value through Mar 2026 reached 84.93%, down 130.0%, while the annual FY2025 figure was 87.09%, 152.0% up from the prior year.
  • Gross Margin hit 79.42% in Q1 2026 for Phathom Pharmaceuticals, down from 86.72% in the prior quarter.
  • Across five years, Gross Margin topped out at 87.5% in Q3 2025 and bottomed at 75.51% in Q4 2023.
  • Average Gross Margin over 4 years is 83.5%, with a median of 86.16% recorded in 2024.
  • Year-over-year, Gross Margin soared 1163bps in 2024 and then tumbled -752bps in 2026.
  • Phathom Pharmaceuticals' Gross Margin stood at 75.51% in 2023, then rose by 15bps to 87.14% in 2024, then decreased by 0bps to 86.72% in 2025, then dropped by -8bps to 79.42% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 79.42%, 86.72%, and 87.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.